In addition to surgical transurethral resection of the bladder tumour, intravesical chemotherapy with mitomycin C (MMC) is commonly used for the treatment of non-muscle-invasive bladder cancer. In this Review, approaches to optimizing MMC therapy through enhanced delivery, as well as maintenance and/or combination treatment regimens, are discussed.
- Homayoun Zargar
- Jonathan Aning
- Peter Black
